Cargando…
The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage?
BACKGROUND: Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir, Amprenavir and Darunavir which can select L76V. Beside an enhancement of resistanc...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049128/ https://www.ncbi.nlm.nih.gov/pubmed/21314993 http://dx.doi.org/10.1186/1742-6405-8-7 |
_version_ | 1782199207612907520 |
---|---|
author | Wiesmann, Frank Vachta, Jan Ehret, Robert Walter, Hauke Kaiser, Rolf Stürmer, Martin Tappe, André Däumer, Martin Berg, Thomas Naeth, Gudrun Braun, Patrick Knechten, Heribert |
author_facet | Wiesmann, Frank Vachta, Jan Ehret, Robert Walter, Hauke Kaiser, Rolf Stürmer, Martin Tappe, André Däumer, Martin Berg, Thomas Naeth, Gudrun Braun, Patrick Knechten, Heribert |
author_sort | Wiesmann, Frank |
collection | PubMed |
description | BACKGROUND: Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir, Amprenavir and Darunavir which can select L76V. Beside an enhancement of resistance, L76V is also discussed to confer hypersusceptibility to the drugs Atazanavir and Saquinavir which might enable new treatment strategies by trying to take advantage of particular mutations. RESULTS: Based on a cohort of 47 L76V-positive patients, we examined if there might exist a clinical advantage for L76V-positive patients concerning long-term success of PI-containing regimens in patients with limited therapy options. Genotypic- and phenotypic HIV-resistance tests from 47 mostly multi-resistant, L76V-positive patients throughout Germany were accomplished retrospectively 1999-2009. Five genotype-based drug-susceptibility predictions received from online interpretation-tools for Atazanavir, Saquinavir, Amprenavir and Lopinavir, were compared to phenotype-based predictions that were determined by using a recombinant virus assay along with a Virtual Phenotype™(Virco). The clinical outcome of the L76V-adapted follow-up therapy was determined by monitoring viral load for 96 weeks. CONCLUSIONS: In this analysis, the mostly used interpretation systems overestimated the L76V-mutation concerning Atazanavir- and SQV resistance. In fact, a clear benefit in drug susceptibility for these drugs was observed in phenotype analysis after establishment of L76V. More importantly, long-term therapy success was significantly higher in patients receiving Atazanavir and/or Saquinavir plus one L76V-selecting drug compared to patients without L76V-selecting agents (p = 0.002). In case of L76V-occurrence ATV and/or SQV may represent encouraging options for patients in deep salvage situations. |
format | Text |
id | pubmed-3049128 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-30491282011-03-06 The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? Wiesmann, Frank Vachta, Jan Ehret, Robert Walter, Hauke Kaiser, Rolf Stürmer, Martin Tappe, André Däumer, Martin Berg, Thomas Naeth, Gudrun Braun, Patrick Knechten, Heribert AIDS Res Ther Short Report BACKGROUND: Although being considered as a rarely observed HIV-1 protease mutation in clinical isolates, the L76V-prevalence increased 1998-2008 in some European countries most likely due to the approval of Lopinavir, Amprenavir and Darunavir which can select L76V. Beside an enhancement of resistance, L76V is also discussed to confer hypersusceptibility to the drugs Atazanavir and Saquinavir which might enable new treatment strategies by trying to take advantage of particular mutations. RESULTS: Based on a cohort of 47 L76V-positive patients, we examined if there might exist a clinical advantage for L76V-positive patients concerning long-term success of PI-containing regimens in patients with limited therapy options. Genotypic- and phenotypic HIV-resistance tests from 47 mostly multi-resistant, L76V-positive patients throughout Germany were accomplished retrospectively 1999-2009. Five genotype-based drug-susceptibility predictions received from online interpretation-tools for Atazanavir, Saquinavir, Amprenavir and Lopinavir, were compared to phenotype-based predictions that were determined by using a recombinant virus assay along with a Virtual Phenotype™(Virco). The clinical outcome of the L76V-adapted follow-up therapy was determined by monitoring viral load for 96 weeks. CONCLUSIONS: In this analysis, the mostly used interpretation systems overestimated the L76V-mutation concerning Atazanavir- and SQV resistance. In fact, a clear benefit in drug susceptibility for these drugs was observed in phenotype analysis after establishment of L76V. More importantly, long-term therapy success was significantly higher in patients receiving Atazanavir and/or Saquinavir plus one L76V-selecting drug compared to patients without L76V-selecting agents (p = 0.002). In case of L76V-occurrence ATV and/or SQV may represent encouraging options for patients in deep salvage situations. BioMed Central 2011-02-13 /pmc/articles/PMC3049128/ /pubmed/21314993 http://dx.doi.org/10.1186/1742-6405-8-7 Text en Copyright ©2011 Wiesmann et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Report Wiesmann, Frank Vachta, Jan Ehret, Robert Walter, Hauke Kaiser, Rolf Stürmer, Martin Tappe, André Däumer, Martin Berg, Thomas Naeth, Gudrun Braun, Patrick Knechten, Heribert The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? |
title | The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? |
title_full | The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? |
title_fullStr | The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? |
title_full_unstemmed | The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? |
title_short | The L76V mutation in HIV-1 protease is potentially associated with hypersusceptibility to protease inhibitors Atazanavir and Saquinavir: is there a clinical advantage? |
title_sort | l76v mutation in hiv-1 protease is potentially associated with hypersusceptibility to protease inhibitors atazanavir and saquinavir: is there a clinical advantage? |
topic | Short Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3049128/ https://www.ncbi.nlm.nih.gov/pubmed/21314993 http://dx.doi.org/10.1186/1742-6405-8-7 |
work_keys_str_mv | AT wiesmannfrank thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT vachtajan thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT ehretrobert thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT walterhauke thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT kaiserrolf thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT sturmermartin thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT tappeandre thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT daumermartin thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT bergthomas thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT naethgudrun thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT braunpatrick thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT knechtenheribert thel76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT wiesmannfrank l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT vachtajan l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT ehretrobert l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT walterhauke l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT kaiserrolf l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT sturmermartin l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT tappeandre l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT daumermartin l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT bergthomas l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT naethgudrun l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT braunpatrick l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage AT knechtenheribert l76vmutationinhiv1proteaseispotentiallyassociatedwithhypersusceptibilitytoproteaseinhibitorsatazanavirandsaquinaviristhereaclinicaladvantage |